Long-Term Survival Benefit With PD-1 Monotherapy Correlated With High PD-L1 Expression in Advanced NSCLC

Biagio Ricciuti, MD, discusses the need to improve the identification of patients with advanced non–small cell lung cancer that benefit most from immune checkpoint inhibition.

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Boston ,Biagio Ricciuti ,Department Of Medicine At Dana Farber Cancer Institute ,International Association ,Lung Cancer ,D ,Patients With Advanced Non Small Cell Lung Cancer ,